This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Influenza and Pneumococcal Vaccines

Nicholas Fiebach, MD; William Beckett, MD, MPH

Arch Intern Med. 1994;154(22):2545-2557.

Abstract
Influenza and pneumococcal infections are important causes of hospitalization and death among individuals who are elderly or who have chronic illnesses. Influenza and pneumococcal vaccines may prevent these infections and their complications, but most high-risk patients have not received them. Doubts about their effectiveness, fears of side effects, and the lack of programs to promote their use contribute to the underuse of these vaccines. Although adequate controlled trials in high-risk patients are lacking, there is observational evidence that they are moderately effective, reducing serious complications of influenza and pneumococcal infections by about one-half. They are cost-effective compared with other preventive interventions and may be cost saving. Their safety has been demonstrated in numerous studies. Health care providers should promote influenza and pneumococcal vaccination. Strategies that have been shown to be successful in increasing the use of these vaccines include provider education and feedback, flagging charts of vaccination candidates, mailed reminders to patients without fall appointments, standing orders for nurses to administer the vaccines, walk-in vaccination clinics, and vaccination of hospitalized patients at discharge.

(Arch Intern Med. 1994;154:2545-2557)

Author Affiliations
From the Sections of General Internal Medicine (Drs Fiebach and Beckett) and Pulmonary and Critical Care Medicine (Dr Beckett), Department of Internal Medicine, and Department Epidemiology and Public Health (Dr Beckett), Yale University School of Medicine, New Haven, Conn, and Department of Medicine, Norwalk (Conn) Hospital (Dr Fiebach).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cost-Benefit Analysis of a New HEDIS Performance Measure for Pneumococcal Vaccination
Ahmed et al.
Med Decis Making 2002;22:S58-S66.
ABSTRACT  

The humoral immune response to influenza vaccination in lung transplant patients
Mazzone et al.
Eur Respir J 2001;18:971-976.
ABSTRACT | FULL TEXT  

Influenza and pneumococcal vaccination: patient perceptions
Findlay et al.
Postgrad. Med. J. 2000;76:215-217.
ABSTRACT | FULL TEXT  

Increasing Influenza and Pneumococcal Vaccination and Tuberculosis Screening among Residents of Colorado Long-Term Care Facilities
Schluter et al.
Eval Health Prof 1999;22:466-483.
ABSTRACT  

Impact of Trace Elements and Vitamin Supplementation on Immunity and Infections in Institutionalized Elderly Patients: A Randomized Controlled Trial
Girodon et al.
Arch Intern Med 1999;159:748-754.
ABSTRACT | FULL TEXT  

Targeting pneumococcal vaccination to high-risk groups: a feasibility study in one general practice
Siriwardena
Postgrad. Med. J. 1999;75:208-212.
ABSTRACT | FULL TEXT  

Primary Care Physicians and Health Promotion
Poland et al.
NEJM 1996;335:599-600.
FULL TEXT